Advances in Iron Deficiency Management in Chronic Kidney Disease: Insights into Pathophysiology, Diagnosis, and Therapeutic Approaches

Advances in Iron Deficiency Management in Chronic Kidney Disease: Insights into Pathophysiology, Diagnosis, and Therapeutic Approaches | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Advances in Iron Deficiency Management in Chronic Kidney Disease: Insights into Pathophysiology, Diagnosis, and Therapeutic Approaches Collince Odiwuor Ogolla, Lucy W. Karani, Stanslaus Musyoki, Phidelis Maruti This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5729312/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Iron deficiency is very common and is clinically significant in patients with chronic kidney disease (CKD). It contributes to anemia and adversely affects outcomes in these patients, including quality of life, and survival. For all the advancements in our understanding of iron metabolism, the optimal methods for treating deficiency in patients with CKD continue to be an area of active research. Objective: The focus of this review is to describe the advances in the pathophysiology, diagnosis, and management of iron deficiency in CKD, emphasizing its biomarker value and the efficacy of oral versus intravenous (IV) iron supplementation. Methods: One hundred twenty patients with chronic kidney disease (stage 3 to 5) suffering from anemia due to iron deficiency were included in this prospective, observational study. They were assigned to either Group A (mild to moderate iron deficiency anemia [IDA], n=60) or Group B (severe IDA, n=60), according to the severity of iron deficiency. Group A received oral iron supplementation, whereas Group B received IV iron therapy. Various parameters on lab tests were measured (initial and after the treatment duration of 8 weeks) for assessment: serum ferritin, transferrin saturation (TSAT), soluble transferrin receptor (sTfR), and serum hepcidin levels. The primary outcome was change in hemoglobin levels, whereas change in iron biomarkers counted as secondary outcomes. Results: The efficacy of IV iron therapy was superior to oral iron supplementation in increasing hemoglobin concentrations and iron parameters (p<0.05). In Group B, the mean increase in hemoglobin concentration was 2.3 g/dL, along with impressive data regarding serum ferritin, TSAT, and sTfR. Elevation in hepcidin levels was significant in severe iron deficiency, indicating that less iron was available for erythropoiesis. The comparison of sTfR as a diagnostic marker showed it to be a better indicator than the traditional markers, such as ferritin, under inflammatory conditions. Conclusion: IV iron supplementation is better than oral iron for treating severe iron deficiency in patients with CKD, leading to better clinical outcomes. New biomarkers, such as sTfR, are much better in evaluating iron status in CKD patients than before, especially in those with concurrent inflammation. All these weighs heavily toward individualized management of the disease. Iron deficiency chronic kidney disease Introduction Iron deficiency states are found mostly and widely in CKD patients - this is responsible for IDA and makes CKD a more serious medical problem. Major common complication found in patients with CKD, approximately between 30 to 50 per cent, occurs in these patients depending on various factors of both its stage and the presence of comorbidities such as diabetes and hypertension [ 1 ]. Absolute and functional iron deficiencies were very important causes of anemia in CKD; the latter was usually associated with disorders of iron metabolism and the inflammation associated with the kidney alteration [ 2 ]. The pathophysiology of iron deficiency in chronic kidney disease is multifactorial, with the most important being reduced erythropoietin production, impaired iron absorption, and increased hepcidin levels. via decreased renal clearance and inflammation in chronic kidney disease, hepcidin is upregulated and causes reduced absorption of iron from the gastrointestinal tract while trapping iron in macrophages and hepatocytes making it unavailable for erythropoiesis [ 3 , 4 ]. Alterations in iron metabolism are responsible for the functional iron deficiency seen in CKD, although stores or excess iron are available at times. This anemia due to CHK is further compounded by the reduced survival of red blood cells as well as poor response to erythropoiesis-stimulating agents (ESAs) [ 5 ]. Good diagnosis of iron deficiency in CKD is compromised by the linear correlation of anemia with inflammation and differentials of established iron parameters in kidney dysfunction. It has always been the practice to measure serum ferritin and transferrin saturation (TSAT) to evaluate iron status; however, these indicators can be influenced by the inflammatory cytokines, which leaves room for misdiagnosis [ 6 ]. Emerging biomarkers like soluble transferrin receptor (sTfR) provide newer and more reliable measures of iron status in patients suffering from CKD, displacing the traditional markers whose values become unreliable with inflammation [ 7 ]. Iron deficiency treatment in CKD includes oral iron therapy, intravenous iron therapy, or both, depending on the state of deficiency the individual is experiencing and the patient's condition. Oral iron is usually the first treatment for mild and moderate iron deficiency; however, in more severe cases or in patients with a very poor gastrointestinal tolerance, it becomes much less effective [ 8 ]. On the contrary, IV iron administration is a more straightforward way to restore iron stores, especially in advance CKD patients or dialysis patients [ 9 ]. Thus, recent studies have proven superiority to oral iron treatment with regard to both improving iron parameters and hemoglobin levels and overall management of anemia in CKD patients [ 10 ]. Research is currently continuing into the best treatment regimen concerning type and amount of iron. With increasing awareness about the pathophysiology, diagnostic issues, and therapeutics of iron deficiency in CKD, this study aims to assess what is new in the management of this condition. We discuss the potential of biomarkers in the diagnosis of iron deficiency, measure and compare the benefits of oral and IV iron supplementation, and study the clinical outcomes associated with these two approaches in CKD patients. Methods It was a prospective, observational study for a period of 12 months. One hundred and twenty patients aged between 30 and 75 years diagnosed with chronic kidney disease (CKD) stages 3 to 5 and with manifestations in the form of iron deficiency anemia (IDA) were enrolled from the tertiary care hospital. They had hemoglobin levels below 12 g/dL in serum and evidence of iron deficiency in laboratory reports with serum ferritin below 100 ng/mL and transferrin saturation (TSAT) below 20%. Active infection, malignancy, recent blood transfusion (up to 3 months), and severely hepatic dysfunction form the exclusion criteria. Written informed consent was obtained from each participant, and the study obtained permission from the institutional ethics committee. They are placed into two groups on the basis of the severity of the deficiency for iron: Group A consisting of 60 patients with mild to moderate IDA and Group B consisting of 60 patients with severe IDA. Mild to moderate IDA were considered to have serum ferritin values of 30 to 100 ng/mL and TSAT 20%-30%. Patients consisting of serum ferritin values less than 30 ng/mL and TSAT values less than 20% are included in Group B. Data Collection and Laboratory Parameters Clinical data were collected on demographics, medical history, and drugs on admission. Laboratory assessments involved complete blood count (CBC), serum ferritin, transferrin saturation, sTfR, and serum hepcidin levels. The concentration of sTfR and hepcidin were determined via enzyme-linked immunosorbent assay (ELISA) kits according to manufacturer's instructions. Blood was collected after fasting overnight, and all samples were done within 4 hours of collection. In terms of serum iron and total iron-binding capacity (TIBC), TSAT was calculated to drive iron status. Such TSAT could be expressed in terms of percentage using the ratio of serum iron to TIBC. The classification on severity of anemia is in g/dL of hemoglobin, 12 normal. Group A patients with mild to moderate IDA attended oral iron therapy with ferrous sulfate of 325 mg a day. Group B patients had severe IDA and received intravenous (IV) iron sucrose (1000 mg over 2 weeks). Both groups were followed for a period of 8 weeks to assess treatment efficacy. The primary outcome was the change in hemoglobin levels, while secondary outcomes included changes in serum ferritin, TSAT, and sTfR levels. The adherence to oral iron in Group A was measured by pill count and patient self-reporting, while adherence to IV iron was followed during follow-up visits. Adverse events related to treatments were monitored for the entire period of study. For Group A, gastrointestinal adverse effects like nausea, constipation, and abdominal discomfort were recorded. For Group B, infusion-related reactions, such as flushing, headache, and dizziness, were noted during infusion sessions and for 24 hours after each infusion. The statistical analysis was performed using SPSS version 25.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. Continuous variables are expressed as means ± standard deviation (SD), while categorical variables are presented as frequencies and percentages. Differences between groups in baseline and post-treatment parameters were analyzed using paired and unpaired t-tests for continuous data and by applying chi-square tests for categorical data. A threshold of < 0.05 was stated as significant. The relationship between hepcidin levels and iron parameters was determined using Pearson's correlation coefficient. The ethical principles according to the Declaration of Helsinki were observed during the entire research process. Participants received well-detailed information about the study and signed informed consent before taking part in the research. The confidentiality of the patients' information was maintained throughout the study. Other adverse events were reported to the institutional review board. Results It primarily focused on looking into new developments in iron deficiency management in chronic kidney disease (CKD) patients alongside an extensive investigation of pathophysiology, diagnosis strategies, and therapeutic modalities. For the present study, 120 CKD patients aged between 30 and 75 years were recruited. All subjects had been diagnosed with CKD stages 3 to 5 and were found to have findings suggestive of iron deficiency anemia (IDA). Only two types of study sample groups were created based on severity of iron deficiency: Group A (mild to moderate IDA, n = 60) and Group B (severe IDA, n = 60). Collected data include clinical parameters, laboratory test results, and treatment outcomes. Pathophysiology of Iron Deficiency in CKD The findings indicates that the pathophysiology of iron deficiency in CKD derives from a combination of reduced renal erythropoietin production, increased hepcidin levels, and impaired gastrointestinal iron absorption. Because it is mainly elevated in CKD, hepcidin, one of the key regulators of iron homeostasis, becomes an additional limiting factor for iron availability for erythropoiesis. Table 1 shows that Group A and Group B average hepcidin showed significantly elevated levels with a mean of 130.5 ng/mL (± 25.4 ng/mL) in Group A and 200.4 ng/mL (± 45.6 ng/mL) in Group B. The elevated levels of hepcidin were accompanied with low serum iron and ferritin levels that reflect impaired mobilization of iron from stores. Diagnosis of Iron Deficiency in CKD Diagnosis of iron deficiency in patients with CKD becomes trickier as there is so much overlapping between anemia and inflammation that is frequent with such individuals. The most important of which is that for iron deficiency diagnosis is serum ferritin and transferrin saturation (TSAT). Apart from these, frankly showing other noticeable markers such as soluble transferrin receptor (sTfR) has recently gained priority in the detection of iron deficiency. Other markers, however, such as soluble transferrin receptor (sTfR), have taken the place of traditional standard iron markers since they can show the iron status without being influenced by inflammatory conditions. Our cohort is summarized in Table 2 with respect to diagnostic performance of these biomarkers. The mean TSAT was significantly higher in Group A than in Group B (25 versus 15%), confirming the severe iron deficiency in the latter group. Therapeutic modalities: Oral versus Intravenous Iron Therapy Iron supplements are at the mainstream in supplement treatment for iron-deficient patients with CKD. This study sought to prove whether oral or intravenous iron would best improve iron status and hemoglobin values. Group A received oral iron supplements, and Group B received IV iron, as shown by the results of this Table 3 on treatment intervention. Group A: 60 patients receiving oral iron (ferrous sulfate 325 mg daily) achieved an average hemoglobin increase of 1.5 g/dL after 8 weeks. However, a significant improvement in iron parameters was observed in only 40% of patients. Group B: 60 patients have been treated with intravenous iron (iron sucrose 1000 mg over 2 weeks). They respond better with an average increase of 2.2 g/dL in hemoglobin and an accompanying improvement in TSAT and ferritin levels, as seen in Table 3 . Table 1 Pathophysiology Markers in CKD Patients with Iron Deficiency Parameter Group A (n = 60) Group B (n = 60) p-value Hepcidin (ng/mL) 130.6 ± 25.4 200.3 ± 45.6 < 0.001 Serum Iron (µg/dL) 40.6 ± 5.1 32.5 ± 4.8 < 0.01 Ferritin (ng/mL) 150.3 ± 30.3 100.4 ± 27.5 < 0.05 Table 2 Diagnostic Biomarkers for Iron Deficiency in CKD Marker Group A (n = 60) Group B (n = 60) Sensitivity (%) Specificity (%) Serum Ferritin (ng/mL) 150.3 ± 30.3 100.3 ± 27.5 85 78 TSAT (%) 25 ± 4.5 15 ± 3.6 90 83 sTfR (mg/L) 2.3 ± 0.8 3.5 ± 1.2 88 85 Table 3 Hemoglobin and Iron Parameter Changes with Oral vs IV Iron Group Treatment Baseline Hb (g/dL) Hb after 8 weeks (g/dL) Ferritin Change (ng/mL) TSAT Change (%) Group A (Oral) Ferrous sulfate 9.6 ± 1.2 11.0 ± 1.3 + 50.3 ± 15.2 + 10 ± 4.6 Group B (IV) Iron sucrose 8.3 ± 1.3 10.5 ± 1.1 + 120.5 ± 30.4 + 20 ± 5.2 Adverse Effects and Treatment Tolerability Both oral iron and intravenous iron therapies were well tolerated in general. In Group A, 15% of the patients experienced gastrointestinal side effects (nausea, constipation) which led to stopping or reducing the dose of treatment. Only 5% of patients in Group B reported mild infusion-related side effects such as transient flushing and mild headache. Discussion Iron deficiency is one of the most common and serious comorbidities in chronic kidney disease (CKD) patients. It is well recognized to cause anemia and significantly compromise quality of life, cardiovascular health, and overall survival among CKD patients. In recent years, a phenomenal amount of changes have occurred in the context of understanding, diagnosis, and management of iron deficiency in CKD based on better insights into the underlying mechanisms and development of improved therapeutic options. Most of the time, iron deficiency in CKD is because of disturbed iron homeostasis. Hepcidin is one of the most important regulators of the iron availability in the body because it is an acute-phase reactant that raises the levels; thus, it prevents the entry of iron in the intestine and also releases iron from the macrophage pool into the bloodstream. B) The mean hepcidin levels in groups A and B were significantly different because of severe iron deficiency (Group B) when compared to mild to moderate deficiency (Group A), confirming hepcidin role in iron regulation (Table 1 ). Previous studies also reported elevated hepcidin levels in patients suffering from CKD and advocate hepcidin as a possible therapeutic target in IDA management in this population [ 11 , 12 ]. These data also support the statement that high hepcidin value is linked with low levels of serum iron and ferritin. It means here that iron deficiency is not the result of poor consumption or absorption of iron in diet but is actually an abnormal change-in iron homeostasis. Studies show that high hepcidin levels could independently predict anemic status in CKD patients and correlate their levels to the severity of anemia [ 13 , 14 ]. In fact, decreased erythropoietin production in CKD has worsened anemia and increased the importance of iron supplementation for treatment options. Accurate iron deficiency diagnosis in CKD is confounding by the presence of overlapping inflammation which alters iron parameters. Traditional markers including serum ferritin and TSAT generally have limitations in CKD according to how changes may be caused by infection and inflammation in our cohort. Novel biomarkers such as soluble transferrin receptor (sTfR), on the other hand, are increasingly being recognized in that regard for their capability of reflecting iron status independent of inflammation. In this study, sTfR levels were significantly higher in patients with severe iron deficiency (Group B), suggesting it may help in the diagnosis of IDA for CKD patients with concurrent inflammation (Table 2 ). This is in agreement with recent research findings which suggest that sTfR is a more reliable marker of iron deficiency in CKD compared to more traditional markers such as ferritin [ 15 , 16 ]. Interestingly, TSAT turned out to be a sensitive estimator of iron deficiency in our cohort, postulating higher sensitivity and specificity in comparison to ferritin, which may be biased due to inflammation. This is what the European Renal Association reveals in guidelines stressing multi-biomarker use for iron deficiency diagnosis in CKD [ 17 ]. A thus-defined profile composed of ferritin, TSAT, and sTfR would probably provide a better picture of iron status in CKD patients. Management of iron deficiency in CKD is one of the cornerstones of treatment, since it relates directly to the anemia and the need for erythropoiesis-stimulating agents (ESAs). The present study assessed the impact of oral versus intravenous (IV) iron supplementation in patients with CKD. The results indicated that IV iron therapy was significantly superior to oral iron in terms of improvement in hemoglobin and iron parameters (Table 3 ). Group B, which received IV iron, showed marked improvement in hemoglobin (2.2 g/dL) as well as important ferritin and TSAT levels-an excellent efficient iron replenishment. This is in accordance with the results of several randomized controlled trials (RCTs) and meta-analyses showing IV iron superiority to oral iron in CKD patients, most especially in those with severe IDA or dialysis [ 18 , 19 ]. The higher efficacy of IV iron is expected because of its high bioavailability and the delivery of the iron directly into the bloodstream, whereas oral forms are passed through the gut and should not be dependent on mechanisms, which are often deranged in CKD. However, oral iron usually works in mild deficiencies, but in these patients gastrointestinal side effects have recorded as high as 40%, as reported in our study. Also, poor compliance with oral intake and the slow onset of action limit its use in severe cases [ 20 ]. It has a higher initial cost, but IV iron is generally well tolerated, with fewer adverse effects. In our cohort, 5% of Group B experienced mild infusion-related reactions such as those associated with flushing and headache. These findings are consistent with studies that report a low incidence of serious adverse effects from IV iron therapy, especially when appropriate monitoring and administration protocols are followed [ 21 ]. Conclusion Management of iron deficiency is one of the prime issues in chronic kidney disease (CKD) scenarios that lead to the formation of anemia in a patient and affect the outcomes of the patient significantly. Our study indicates that intravenous (IV) iron therapy is a better intervention than oral iron supplementation for improving hemoglobin levels and correcting iron deficiencies, particularly for the more severe cases. The new biomarkers such as soluble transferrin receptor (sTfR) can give a more accurate and reliable indication for diagnosing iron deficiency in CKD patients, especially when inflammation is present which confounds traditional markers such as ferritin and transferrin saturation (TSAT). These findings also stress the individualized approaches to treating iron deficiency in CKD: IV iron should be first-line therapy for those patients manifestly deficient in iron while oral administration may still be applicable to those with less severe deficiency. Moreover, further studies need to be conducted to determine the ideal dose schedules for IV iron and assess iron therapy for long-term clinical outcomes relating to cardiovascular events and survival of CKD patients. Ultimately addressing iron deficiency in CKD better through the appropriate pathology and a safe and effective therapeutic regime would make such anemia much easier to control and minimize or eliminate the need for erythropoiesis-stimulating agents (ESAs) while improving the quality of life of these patients. Declarations Conflicts of Interest: There is no conflict of interest regarding this article Funding: There was no funding received for this study Data availability: The data of the findings of this study are all shared on this article Consent for publication: All authors has given their consent for publication of this article Ethics approval and consent to participate: The study observed ethics according to Helsinki declaration and all participants signed voluntary written informed consent form. Authors’ contributions: All authors reviewed this article Acknowledgment: N/A Authors’ Information: N/A References KDOQI Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO) 2012; 2(4): 288-296. Macdougall IC, et al. "The role of hepcidin in iron homeostasis and its implications in chronic kidney disease." Nephrology Dialysis Transplantation 2015; 30(2): 311-316. Ganz T, Nemeth E. "Hepcidin and iron homeostasis." Biochimica et Biophysica Acta 2009; 1790(7): 718-723. Kautz L, et al. "Hepcidin regulation by anemia and iron in the mouse." Blood 2008; 112(1): 63-70. Stryjewski ME, et al. "Hepcidin: a regulator of iron metabolism." Blood Reviews 2014; 28(4): 173-181. Klaus F, et al. "Soluble transferrin receptor as a diagnostic marker of iron deficiency in patients with chronic kidney disease." Nephrology Dialysis Transplantation 2011; 26(8): 2521-2527. El-Shahawy M, et al. "Soluble transferrin receptor and its relationship with iron status in patients with chronic kidney disease." Kidney International 2012; 81(5): 485-491. Fishbane S, et al. "A meta-analysis of intravenous iron therapy for anemia in chronic kidney disease." American Journal of Kidney Diseases 2012; 60(6): 928-937. Coyne DW, et al. "Intravenous iron therapy in chronic kidney disease." Nephrology Dialysis Transplantation 2007; 22(11): 3159-3164. Van Wyck DB, et al. "The safety of intravenous iron sucrose in the treatment of iron deficiency in chronic kidney disease." Nephrology Dialysis Transplantation 2005; 20(5): 957-963. Macdougall IC, et al. "The role of hepcidin in iron homeostasis and its implications in chronic kidney disease." Nephrology Dialysis Transplantation 2015; 30(2): 311-316. Kautz L, et al. "Hepcidin regulation by anemia and iron in the mouse." Blood 2008; 112(1): 63-70. Ganz T, Nemeth E. "Hepcidin and iron homeostasis." Biochimica et Biophysica Acta 2009; 1790(7): 718-723. Stryjewski ME, et al. "Hepcidin: a regulator of iron metabolism." Blood Reviews 2014; 28(4): 173-181. Klaus F, et al. "Soluble transferrin receptor as a diagnostic marker of iron deficiency in patients with chronic kidney disease." Nephrology Dialysis Transplantation 2011; 26(8): 2521-2527. El-Shahawy M, et al. "Soluble transferrin receptor and its relationship with iron status in patients with chronic kidney disease." Kidney International 2012; 81(5): 485-491. KDIGO. "KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease." Kidney International Supplements 2012; 2(4): 288-296. Coyne DW, et al. "Intravenous iron therapy in chronic kidney disease." Nephrology Dialysis Transplantation 2007; 22(11): 3159-3164. Fishbane S, et al. "A meta-analysis of intravenous iron therapy for anemia in chronic kidney disease." American Journal of Kidney Diseases 2012; 60(6): 928-937. Jager KJ, et al. "Oral iron therapy in patients with chronic kidney disease." Kidney International 2013; 83(3): 583-588. Van Wyck DB, et al. "The safety of intravenous iron sucrose in the treatment of iron deficiency in chronic kidney disease." Nephrology Dialysis Transplantation 2005; 20(5): 957-963. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5729312","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":396782995,"identity":"78106421-2fc3-414b-be89-d49b8ca60bd9","order_by":0,"name":"Collince Odiwuor Ogolla","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA+UlEQVRIiWNgGAWjYHACxgMPgCQfO2MDkLIBCTQeIKTnQAKQYGMGa0kDaWkgVguYfRgigk85P//iAwcSauzk2JiZ2x78qDhvt7b9MNCWGptoXFokZzxLOJBwLNkY6LB2w54zt5O3nUkEajmWltuAQ4vBjTMGBxLYDiS2MTO2STO23U42OwDUwthwmICWfzAt/84lm51/SEDL+R4DoHqYloYDdmY3CNgiOYMt4UBiH9gvbZI9x5ITzG4AbUnA4xd+/sMHH3z4ZifHz97+TOJHjZ292fn0hw8+1Njg1MIgkYDKTwSrTMBQh2zNAVS+PT7Fo2AUjIJRMDIBAH2CZQyGr5moAAAAAElFTkSuQmCC","orcid":"","institution":"Kisii University","correspondingAuthor":true,"prefix":"","firstName":"Collince","middleName":"Odiwuor","lastName":"Ogolla","suffix":""},{"id":396782996,"identity":"3b961bf9-b82e-4a43-ab0f-9cbcfb4cb941","order_by":1,"name":"Lucy W. Karani","email":"","orcid":"","institution":"Kisii University","correspondingAuthor":false,"prefix":"","firstName":"Lucy","middleName":"W.","lastName":"Karani","suffix":""},{"id":396782997,"identity":"4d6dc895-7ec8-4023-8751-b8c95acb1166","order_by":2,"name":"Stanslaus Musyoki","email":"","orcid":"","institution":"South Eastern Kenya University","correspondingAuthor":false,"prefix":"","firstName":"Stanslaus","middleName":"","lastName":"Musyoki","suffix":""},{"id":396782998,"identity":"94574f6c-ca94-408b-bac1-69acf288aab4","order_by":3,"name":"Phidelis Maruti","email":"","orcid":"","institution":"Kisii University","correspondingAuthor":false,"prefix":"","firstName":"Phidelis","middleName":"","lastName":"Maruti","suffix":""}],"badges":[],"createdAt":"2024-12-29 09:38:10","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5729312/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5729312/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":72862410,"identity":"2a092115-07d4-41de-a70e-e00c01cd56c1","added_by":"auto","created_at":"2025-01-03 04:08:22","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":411350,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5729312/v1/f62af95a-137e-4de8-9b63-16fecaa926da.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Advances in Iron Deficiency Management in Chronic Kidney Disease: Insights into Pathophysiology, Diagnosis, and Therapeutic Approaches","fulltext":[{"header":"Introduction","content":"\u003cp\u003eIron deficiency states are found mostly and widely in CKD patients - this is responsible for IDA and makes CKD a more serious medical problem. Major common complication found in patients with CKD, approximately between 30 to 50 per cent, occurs in these patients depending on various factors of both its stage and the presence of comorbidities such as diabetes and hypertension [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Absolute and functional iron deficiencies were very important causes of anemia in CKD; the latter was usually associated with disorders of iron metabolism and the inflammation associated with the kidney alteration [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. The pathophysiology of iron deficiency in chronic kidney disease is multifactorial, with the most important being reduced erythropoietin production, impaired iron absorption, and increased hepcidin levels. via decreased renal clearance and inflammation in chronic kidney disease, hepcidin is upregulated and causes reduced absorption of iron from the gastrointestinal tract while trapping iron in macrophages and hepatocytes making it unavailable for erythropoiesis [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Alterations in iron metabolism are responsible for the functional iron deficiency seen in CKD, although stores or excess iron are available at times. This anemia due to CHK is further compounded by the reduced survival of red blood cells as well as poor response to erythropoiesis-stimulating agents (ESAs) [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eGood diagnosis of iron deficiency in CKD is compromised by the linear correlation of anemia with inflammation and differentials of established iron parameters in kidney dysfunction. It has always been the practice to measure serum ferritin and transferrin saturation (TSAT) to evaluate iron status; however, these indicators can be influenced by the inflammatory cytokines, which leaves room for misdiagnosis [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Emerging biomarkers like soluble transferrin receptor (sTfR) provide newer and more reliable measures of iron status in patients suffering from CKD, displacing the traditional markers whose values become unreliable with inflammation [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIron deficiency treatment in CKD includes oral iron therapy, intravenous iron therapy, or both, depending on the state of deficiency the individual is experiencing and the patient's condition. Oral iron is usually the first treatment for mild and moderate iron deficiency; however, in more severe cases or in patients with a very poor gastrointestinal tolerance, it becomes much less effective [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. On the contrary, IV iron administration is a more straightforward way to restore iron stores, especially in advance CKD patients or dialysis patients [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Thus, recent studies have proven superiority to oral iron treatment with regard to both improving iron parameters and hemoglobin levels and overall management of anemia in CKD patients [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. Research is currently continuing into the best treatment regimen concerning type and amount of iron. With increasing awareness about the pathophysiology, diagnostic issues, and therapeutics of iron deficiency in CKD, this study aims to assess what is new in the management of this condition. We discuss the potential of biomarkers in the diagnosis of iron deficiency, measure and compare the benefits of oral and IV iron supplementation, and study the clinical outcomes associated with these two approaches in CKD patients.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eIt was a prospective, observational study for a period of 12 months. One hundred and twenty patients aged between 30 and 75 years diagnosed with chronic kidney disease (CKD) stages 3 to 5 and with manifestations in the form of iron deficiency anemia (IDA) were enrolled from the tertiary care hospital. They had hemoglobin levels below 12 g/dL in serum and evidence of iron deficiency in laboratory reports with serum ferritin below 100 ng/mL and transferrin saturation (TSAT) below 20%. Active infection, malignancy, recent blood transfusion (up to 3 months), and severely hepatic dysfunction form the exclusion criteria. Written informed consent was obtained from each participant, and the study obtained permission from the institutional ethics committee.\u003c/p\u003e \u003cp\u003eThey are placed into two groups on the basis of the severity of the deficiency for iron: Group A consisting of 60 patients with mild to moderate IDA and Group B consisting of 60 patients with severe IDA. Mild to moderate IDA were considered to have serum ferritin values of 30 to 100 ng/mL and TSAT 20%-30%. Patients consisting of serum ferritin values less than 30 ng/mL and TSAT values less than 20% are included in Group B. Data Collection and Laboratory Parameters Clinical data were collected on demographics, medical history, and drugs on admission. Laboratory assessments involved complete blood count (CBC), serum ferritin, transferrin saturation, sTfR, and serum hepcidin levels. The concentration of sTfR and hepcidin were determined via enzyme-linked immunosorbent assay (ELISA) kits according to manufacturer's instructions. Blood was collected after fasting overnight, and all samples were done within 4 hours of collection. In terms of serum iron and total iron-binding capacity (TIBC), TSAT was calculated to drive iron status. Such TSAT could be expressed in terms of percentage using the ratio of serum iron to TIBC. The classification on severity of anemia is in g/dL of hemoglobin, \u0026lt;\u0026thinsp;10 being severe, 10-11.9 moderate, and \u0026gt;\u0026thinsp;12 normal.\u003c/p\u003e \u003cp\u003eGroup A patients with mild to moderate IDA attended oral iron therapy with ferrous sulfate of 325 mg a day. Group B patients had severe IDA and received intravenous (IV) iron sucrose (1000 mg over 2 weeks). Both groups were followed for a period of 8 weeks to assess treatment efficacy. The primary outcome was the change in hemoglobin levels, while secondary outcomes included changes in serum ferritin, TSAT, and sTfR levels. The adherence to oral iron in Group A was measured by pill count and patient self-reporting, while adherence to IV iron was followed during follow-up visits. Adverse events related to treatments were monitored for the entire period of study. For Group A, gastrointestinal adverse effects like nausea, constipation, and abdominal discomfort were recorded. For Group B, infusion-related reactions, such as flushing, headache, and dizziness, were noted during infusion sessions and for 24 hours after each infusion.\u003c/p\u003e \u003cp\u003eThe statistical analysis was performed using SPSS version 25.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. Continuous variables are expressed as means\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (SD), while categorical variables are presented as frequencies and percentages. Differences between groups in baseline and post-treatment parameters were analyzed using paired and unpaired t-tests for continuous data and by applying chi-square tests for categorical data. A threshold of \u0026lt;\u0026thinsp;0.05 was stated as significant. The relationship between hepcidin levels and iron parameters was determined using Pearson's correlation coefficient. The ethical principles according to the Declaration of Helsinki were observed during the entire research process. Participants received well-detailed information about the study and signed informed consent before taking part in the research. The confidentiality of the patients' information was maintained throughout the study. Other adverse events were reported to the institutional review board.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eIt primarily focused on looking into new developments in iron deficiency management in chronic kidney disease (CKD) patients alongside an extensive investigation of pathophysiology, diagnosis strategies, and therapeutic modalities. For the present study, 120 CKD patients aged between 30 and 75 years were recruited. All subjects had been diagnosed with CKD stages 3 to 5 and were found to have findings suggestive of iron deficiency anemia (IDA). Only two types of study sample groups were created based on severity of iron deficiency: Group A (mild to moderate IDA, n\u0026thinsp;=\u0026thinsp;60) and Group B (severe IDA, n\u0026thinsp;=\u0026thinsp;60). Collected data include clinical parameters, laboratory test results, and treatment outcomes.\u003c/p\u003e\n\u003ch3\u003ePathophysiology of Iron Deficiency in CKD\u003c/h3\u003e\n\u003cp\u003eThe findings indicates that the pathophysiology of iron deficiency in CKD derives from a combination of reduced renal erythropoietin production, increased hepcidin levels, and impaired gastrointestinal iron absorption. Because it is mainly elevated in CKD, hepcidin, one of the key regulators of iron homeostasis, becomes an additional limiting factor for iron availability for erythropoiesis. Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e shows that Group A and Group B average hepcidin showed significantly elevated levels with a mean of 130.5 ng/mL (\u0026plusmn;\u0026thinsp;25.4 ng/mL) in Group A and 200.4 ng/mL (\u0026plusmn;\u0026thinsp;45.6 ng/mL) in Group B. The elevated levels of hepcidin were accompanied with low serum iron and ferritin levels that reflect impaired mobilization of iron from stores.\u003c/p\u003e\n\u003ch3\u003eDiagnosis of Iron Deficiency in CKD\u003c/h3\u003e\n\u003cp\u003eDiagnosis of iron deficiency in patients with CKD becomes trickier as there is so much overlapping between anemia and inflammation that is frequent with such individuals. The most important of which is that for iron deficiency diagnosis is serum ferritin and transferrin saturation (TSAT). Apart from these, frankly showing other noticeable markers such as soluble transferrin receptor (sTfR) has recently gained priority in the detection of iron deficiency. Other markers, however, such as soluble transferrin receptor (sTfR), have taken the place of traditional standard iron markers since they can show the iron status without being influenced by inflammatory conditions. Our cohort is summarized in Table \u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e with respect to diagnostic performance of these biomarkers. The mean TSAT was significantly higher in Group A than in Group B (25 versus 15%), confirming the severe iron deficiency in the latter group.\u003c/p\u003e\n\u003ch3\u003eTherapeutic modalities: Oral versus Intravenous Iron Therapy\u003c/h3\u003e\n\u003cp\u003eIron supplements are at the mainstream in supplement treatment for iron-deficient patients with CKD. This study sought to prove whether oral or intravenous iron would best improve iron status and hemoglobin values. Group A received oral iron supplements, and Group B received IV iron, as shown by the results of this Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e on treatment intervention.\u003c/p\u003e \u003cp\u003eGroup A: 60 patients receiving oral iron (ferrous sulfate 325 mg daily) achieved an average hemoglobin increase of 1.5 g/dL after 8 weeks. However, a significant improvement in iron parameters was observed in only 40% of patients.\u003c/p\u003e \u003cp\u003eGroup B: 60 patients have been treated with intravenous iron (iron sucrose 1000 mg over 2 weeks). They respond better with an average increase of 2.2 g/dL in hemoglobin and an accompanying improvement in TSAT and ferritin levels, as seen in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePathophysiology Markers in CKD Patients with Iron Deficiency\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eParameter\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGroup A (n\u0026thinsp;=\u0026thinsp;60)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGroup B (n\u0026thinsp;=\u0026thinsp;60)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ep-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHepcidin (ng/mL)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e130.6\u0026thinsp;\u0026plusmn;\u0026thinsp;25.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e200.3\u0026thinsp;\u0026plusmn;\u0026thinsp;45.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSerum Iron (\u0026micro;g/dL)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e40.6\u0026thinsp;\u0026plusmn;\u0026thinsp;5.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e32.5\u0026thinsp;\u0026plusmn;\u0026thinsp;4.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.01\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFerritin (ng/mL)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e150.3\u0026thinsp;\u0026plusmn;\u0026thinsp;30.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e100.4\u0026thinsp;\u0026plusmn;\u0026thinsp;27.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.05\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDiagnostic Biomarkers for Iron Deficiency in CKD\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMarker\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGroup A (n\u0026thinsp;=\u0026thinsp;60)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGroup B (n\u0026thinsp;=\u0026thinsp;60)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSensitivity (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSpecificity (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSerum Ferritin (ng/mL)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e150.3\u0026thinsp;\u0026plusmn;\u0026thinsp;30.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e100.3\u0026thinsp;\u0026plusmn;\u0026thinsp;27.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e85\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e78\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTSAT (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e25\u0026thinsp;\u0026plusmn;\u0026thinsp;4.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e15\u0026thinsp;\u0026plusmn;\u0026thinsp;3.6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e83\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003esTfR (mg/L)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c2\"\u003e \u003cp\u003e2.3\u0026thinsp;\u0026plusmn;\u0026thinsp;0.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.5\u0026thinsp;\u0026plusmn;\u0026thinsp;1.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e88\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e85\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eHemoglobin and Iron Parameter Changes with Oral vs IV Iron\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGroup\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTreatment\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBaseline Hb (g/dL)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHb after 8 weeks (g/dL)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eFerritin Change (ng/mL)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTSAT Change (%)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGroup A (Oral)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFerrous sulfate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e9.6\u0026thinsp;\u0026plusmn;\u0026thinsp;1.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e11.0\u0026thinsp;\u0026plusmn;\u0026thinsp;1.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c5\"\u003e \u003cp\u003e+\u0026thinsp;50.3\u0026thinsp;\u0026plusmn;\u0026thinsp;15.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c6\"\u003e \u003cp\u003e+\u0026thinsp;10\u0026thinsp;\u0026plusmn;\u0026thinsp;4.6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGroup B (IV)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIron sucrose\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e8.3\u0026thinsp;\u0026plusmn;\u0026thinsp;1.3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e10.5\u0026thinsp;\u0026plusmn;\u0026thinsp;1.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c5\"\u003e \u003cp\u003e+\u0026thinsp;120.5\u0026thinsp;\u0026plusmn;\u0026thinsp;30.4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c6\"\u003e \u003cp\u003e+\u0026thinsp;20\u0026thinsp;\u0026plusmn;\u0026thinsp;5.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e\n\u003ch3\u003eAdverse Effects and Treatment Tolerability\u003c/h3\u003e\n\u003cp\u003eBoth oral iron and intravenous iron therapies were well tolerated in general. In Group A, 15% of the patients experienced gastrointestinal side effects (nausea, constipation) which led to stopping or reducing the dose of treatment. Only 5% of patients in Group B reported mild infusion-related side effects such as transient flushing and mild headache.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIron deficiency is one of the most common and serious comorbidities in chronic kidney disease (CKD) patients. It is well recognized to cause anemia and significantly compromise quality of life, cardiovascular health, and overall survival among CKD patients. In recent years, a phenomenal amount of changes have occurred in the context of understanding, diagnosis, and management of iron deficiency in CKD based on better insights into the underlying mechanisms and development of improved therapeutic options. Most of the time, iron deficiency in CKD is because of disturbed iron homeostasis. Hepcidin is one of the most important regulators of the iron availability in the body because it is an acute-phase reactant that raises the levels; thus, it prevents the entry of iron in the intestine and also releases iron from the macrophage pool into the bloodstream. B) The mean hepcidin levels in groups A and B were significantly different because of severe iron deficiency (Group B) when compared to mild to moderate deficiency (Group A), confirming hepcidin role in iron regulation (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Previous studies also reported elevated hepcidin levels in patients suffering from CKD and advocate hepcidin as a possible therapeutic target in IDA management in this population [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. These data also support the statement that high hepcidin value is linked with low levels of serum iron and ferritin. It means here that iron deficiency is not the result of poor consumption or absorption of iron in diet but is actually an abnormal change-in iron homeostasis. Studies show that high hepcidin levels could independently predict anemic status in CKD patients and correlate their levels to the severity of anemia [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. In fact, decreased erythropoietin production in CKD has worsened anemia and increased the importance of iron supplementation for treatment options.\u003c/p\u003e \u003cp\u003eAccurate iron deficiency diagnosis in CKD is confounding by the presence of overlapping inflammation which alters iron parameters. Traditional markers including serum ferritin and TSAT generally have limitations in CKD according to how changes may be caused by infection and inflammation in our cohort. Novel biomarkers such as soluble transferrin receptor (sTfR), on the other hand, are increasingly being recognized in that regard for their capability of reflecting iron status independent of inflammation. In this study, sTfR levels were significantly higher in patients with severe iron deficiency (Group B), suggesting it may help in the diagnosis of IDA for CKD patients with concurrent inflammation (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). This is in agreement with recent research findings which suggest that sTfR is a more reliable marker of iron deficiency in CKD compared to more traditional markers such as ferritin [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Interestingly, TSAT turned out to be a sensitive estimator of iron deficiency in our cohort, postulating higher sensitivity and specificity in comparison to ferritin, which may be biased due to inflammation. This is what the European Renal Association reveals in guidelines stressing multi-biomarker use for iron deficiency diagnosis in CKD [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. A thus-defined profile composed of ferritin, TSAT, and sTfR would probably provide a better picture of iron status in CKD patients.\u003c/p\u003e \u003cp\u003eManagement of iron deficiency in CKD is one of the cornerstones of treatment, since it relates directly to the anemia and the need for erythropoiesis-stimulating agents (ESAs). The present study assessed the impact of oral versus intravenous (IV) iron supplementation in patients with CKD. The results indicated that IV iron therapy was significantly superior to oral iron in terms of improvement in hemoglobin and iron parameters (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Group B, which received IV iron, showed marked improvement in hemoglobin (2.2 g/dL) as well as important ferritin and TSAT levels-an excellent efficient iron replenishment. This is in accordance with the results of several randomized controlled trials (RCTs) and meta-analyses showing IV iron superiority to oral iron in CKD patients, most especially in those with severe IDA or dialysis [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. The higher efficacy of IV iron is expected because of its high bioavailability and the delivery of the iron directly into the bloodstream, whereas oral forms are passed through the gut and should not be dependent on mechanisms, which are often deranged in CKD. However, oral iron usually works in mild deficiencies, but in these patients gastrointestinal side effects have recorded as high as 40%, as reported in our study. Also, poor compliance with oral intake and the slow onset of action limit its use in severe cases [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. It has a higher initial cost, but IV iron is generally well tolerated, with fewer adverse effects. In our cohort, 5% of Group B experienced mild infusion-related reactions such as those associated with flushing and headache. These findings are consistent with studies that report a low incidence of serious adverse effects from IV iron therapy, especially when appropriate monitoring and administration protocols are followed [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e].\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eManagement of iron deficiency is one of the prime issues in chronic kidney disease (CKD) scenarios that lead to the formation of anemia in a patient and affect the outcomes of the patient significantly. Our study indicates that intravenous (IV) iron therapy is a better intervention than oral iron supplementation for improving hemoglobin levels and correcting iron deficiencies, particularly for the more severe cases. The new biomarkers such as soluble transferrin receptor (sTfR) can give a more accurate and reliable indication for diagnosing iron deficiency in CKD patients, especially when inflammation is present which confounds traditional markers such as ferritin and transferrin saturation (TSAT). These findings also stress the individualized approaches to treating iron deficiency in CKD: IV iron should be first-line therapy for those patients manifestly deficient in iron while oral administration may still be applicable to those with less severe deficiency. Moreover, further studies need to be conducted to determine the ideal dose schedules for IV iron and assess iron therapy for long-term clinical outcomes relating to cardiovascular events and survival of CKD patients. Ultimately addressing iron deficiency in CKD better through the appropriate pathology and a safe and effective therapeutic regime would make such anemia much easier to control and minimize or eliminate the need for erythropoiesis-stimulating agents (ESAs) while improving the quality of life of these patients.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eConflicts of Interest:\u0026nbsp;\u003c/strong\u003eThere is no conflict of interest regarding this article\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u0026nbsp;\u003c/strong\u003eThere was no funding received for this study\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability:\u0026nbsp;\u003c/strong\u003eThe data of the findings of this study are all shared on this article\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u0026nbsp;\u003c/strong\u003eAll authors has given their consent for publication of this article\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u003c/strong\u003e The study observed ethics according to Helsinki declaration and all participants signed voluntary written informed consent form.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors’ contributions:\u0026nbsp;\u003c/strong\u003eAll authors reviewed this article\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgment:\u0026nbsp;\u003c/strong\u003eN/A\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors’ Information:\u0026nbsp;\u003c/strong\u003eN/A\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eKDOQI Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. \u003cem\u003eKidney Disease: Improving Global Outcomes (KDIGO)\u003c/em\u003e 2012; 2(4): 288-296.\u003c/li\u003e\n \u003cli\u003eMacdougall IC, et al. \u0026quot;The role of hepcidin in iron homeostasis and its implications in chronic kidney disease.\u0026quot; \u003cem\u003eNephrology Dialysis Transplantation\u003c/em\u003e 2015; 30(2): 311-316.\u003c/li\u003e\n \u003cli\u003eGanz T, Nemeth E. \u0026quot;Hepcidin and iron homeostasis.\u0026quot; \u003cem\u003eBiochimica et Biophysica Acta\u003c/em\u003e 2009; 1790(7): 718-723.\u003c/li\u003e\n \u003cli\u003eKautz L, et al. \u0026quot;Hepcidin regulation by anemia and iron in the mouse.\u0026quot; \u003cem\u003eBlood\u003c/em\u003e 2008; 112(1): 63-70.\u003c/li\u003e\n \u003cli\u003eStryjewski ME, et al. \u0026quot;Hepcidin: a regulator of iron metabolism.\u0026quot; \u003cem\u003eBlood Reviews\u003c/em\u003e 2014; 28(4): 173-181.\u003c/li\u003e\n \u003cli\u003eKlaus F, et al. \u0026quot;Soluble transferrin receptor as a diagnostic marker of iron deficiency in patients with chronic kidney disease.\u0026quot; \u003cem\u003eNephrology Dialysis Transplantation\u003c/em\u003e 2011; 26(8): 2521-2527.\u003c/li\u003e\n \u003cli\u003eEl-Shahawy M, et al. \u0026quot;Soluble transferrin receptor and its relationship with iron status in patients with chronic kidney disease.\u0026quot; \u003cem\u003eKidney International\u003c/em\u003e 2012; 81(5): 485-491.\u003c/li\u003e\n \u003cli\u003eFishbane S, et al. \u0026quot;A meta-analysis of intravenous iron therapy for anemia in chronic kidney disease.\u0026quot; \u003cem\u003eAmerican Journal of Kidney Diseases\u003c/em\u003e 2012; 60(6): 928-937.\u003c/li\u003e\n \u003cli\u003eCoyne DW, et al. \u0026quot;Intravenous iron therapy in chronic kidney disease.\u0026quot; \u003cem\u003eNephrology Dialysis Transplantation\u003c/em\u003e 2007; 22(11): 3159-3164.\u003c/li\u003e\n \u003cli\u003eVan Wyck DB, et al. \u0026quot;The safety of intravenous iron sucrose in the treatment of iron deficiency in chronic kidney disease.\u0026quot; \u003cem\u003eNephrology Dialysis Transplantation\u003c/em\u003e 2005; 20(5): 957-963.\u003c/li\u003e\n \u003cli\u003eMacdougall IC, et al. \u0026quot;The role of hepcidin in iron homeostasis and its implications in chronic kidney disease.\u0026quot; \u003cem\u003eNephrology Dialysis Transplantation\u003c/em\u003e 2015; 30(2): 311-316.\u003c/li\u003e\n \u003cli\u003eKautz L, et al. \u0026quot;Hepcidin regulation by anemia and iron in the mouse.\u0026quot; \u003cem\u003eBlood\u003c/em\u003e 2008; 112(1): 63-70.\u003c/li\u003e\n \u003cli\u003eGanz T, Nemeth E. \u0026quot;Hepcidin and iron homeostasis.\u0026quot; \u003cem\u003eBiochimica et Biophysica Acta\u003c/em\u003e 2009; 1790(7): 718-723.\u003c/li\u003e\n \u003cli\u003eStryjewski ME, et al. \u0026quot;Hepcidin: a regulator of iron metabolism.\u0026quot; \u003cem\u003eBlood Reviews\u003c/em\u003e 2014; 28(4): 173-181.\u003c/li\u003e\n \u003cli\u003eKlaus F, et al. \u0026quot;Soluble transferrin receptor as a diagnostic marker of iron deficiency in patients with chronic kidney disease.\u0026quot; \u003cem\u003eNephrology Dialysis Transplantation\u003c/em\u003e 2011; 26(8): 2521-2527.\u003c/li\u003e\n \u003cli\u003eEl-Shahawy M, et al. \u0026quot;Soluble transferrin receptor and its relationship with iron status in patients with chronic kidney disease.\u0026quot; \u003cem\u003eKidney International\u003c/em\u003e 2012; 81(5): 485-491.\u003c/li\u003e\n \u003cli\u003eKDIGO. \u0026quot;KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease.\u0026quot; \u003cem\u003eKidney International Supplements\u003c/em\u003e 2012; 2(4): 288-296.\u003c/li\u003e\n \u003cli\u003eCoyne DW, et al. \u0026quot;Intravenous iron therapy in chronic kidney disease.\u0026quot; \u003cem\u003eNephrology Dialysis Transplantation\u003c/em\u003e 2007; 22(11): 3159-3164.\u003c/li\u003e\n \u003cli\u003eFishbane S, et al. \u0026quot;A meta-analysis of intravenous iron therapy for anemia in chronic kidney disease.\u0026quot; \u003cem\u003eAmerican Journal of Kidney Diseases\u003c/em\u003e 2012; 60(6): 928-937.\u003c/li\u003e\n \u003cli\u003eJager KJ, et al. \u0026quot;Oral iron therapy in patients with chronic kidney disease.\u0026quot; \u003cem\u003eKidney International\u003c/em\u003e 2013; 83(3): 583-588.\u003c/li\u003e\n \u003cli\u003eVan Wyck DB, et al. \u0026quot;The safety of intravenous iron sucrose in the treatment of iron deficiency in chronic kidney disease.\u0026quot; \u003cem\u003eNephrology Dialysis Transplantation\u003c/em\u003e 2005; 20(5): 957-963.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Iron deficiency, chronic kidney disease","lastPublishedDoi":"10.21203/rs.3.rs-5729312/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5729312/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e Iron deficiency is very common and is clinically significant in patients with chronic kidney disease (CKD). It contributes to anemia and adversely affects outcomes in these patients, including quality of life, and survival. For all the advancements in our understanding of iron metabolism, the optimal methods for treating deficiency in patients with CKD continue to be an area of active research.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eObjective:\u003c/strong\u003e The focus of this review is to describe the advances in the pathophysiology, diagnosis, and management of iron deficiency in CKD, emphasizing its biomarker value and the efficacy of oral versus intravenous (IV) iron supplementation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods:\u003c/strong\u003e One hundred twenty patients with chronic kidney disease (stage 3 to 5) suffering from anemia due to iron deficiency were included in this prospective, observational study. They were assigned to either Group A (mild to moderate iron deficiency anemia [IDA], n=60) or Group B (severe IDA, n=60), according to the severity of iron deficiency. Group A received oral iron supplementation, whereas Group B received IV iron therapy. Various parameters on lab tests were measured (initial and after the treatment duration of 8 weeks) for assessment: serum ferritin, transferrin saturation (TSAT), soluble transferrin receptor (sTfR), and serum hepcidin levels. The primary outcome was change in hemoglobin levels, whereas change in iron biomarkers counted as secondary outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults:\u003c/strong\u003e The efficacy of IV iron therapy was superior to oral iron supplementation in increasing hemoglobin concentrations and iron parameters (p\u0026lt;0.05). In Group B, the mean increase in hemoglobin concentration was 2.3 g/dL, along with impressive data regarding serum ferritin, TSAT, and sTfR. Elevation in hepcidin levels was significant in severe iron deficiency, indicating that less iron was available for erythropoiesis. The comparison of sTfR as a diagnostic marker showed it to be a better indicator than the traditional markers, such as ferritin, under inflammatory conditions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e IV iron supplementation is better than oral iron for treating severe iron deficiency in patients with CKD, leading to better clinical outcomes. New biomarkers, such as sTfR, are much better in evaluating iron status in CKD patients than before, especially in those with concurrent inflammation. All these weighs heavily toward individualized management of the disease.\u003c/p\u003e","manuscriptTitle":"Advances in Iron Deficiency Management in Chronic Kidney Disease: Insights into Pathophysiology, Diagnosis, and Therapeutic Approaches","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-01-03 04:08:02","doi":"10.21203/rs.3.rs-5729312/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1ba79e1e-91d4-42b7-b8ce-3c41e72347fd","owner":[],"postedDate":"January 3rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-01-17T11:23:39+00:00","versionOfRecord":[],"versionCreatedAt":"2025-01-03 04:08:02","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5729312","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5729312","identity":"rs-5729312","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}